uniQure Announces Update on Low-Dose Cohort in Phase I/II
~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean...
Source: globenewswire.com
Year Observations News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Year Observations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Year Observations Today - Breaking & Trending Today
uniQure Inc.: uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington's Disease
~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT (mHTT) observed
Source: finanznachrichten.de